Document is current
Any future updates will be listed below
-
Authors
Ida, Hiroyuki
Watanabe, Yuko https://orcid.org/0000-0002-2735-6985
Sagara, Rieko
Inoue, Yoichi
Fernandez, Jovelle
-
Funding
Funding for this research was provided by:
Takeda Pharmaceutical Company Limited (Takeda Pharmaceutical Company Limited)
- License Information
-
More Information
Article History
Received: 25 February 2022
Accepted: 11 October 2022
First Online: 3 November 2022
Declarations
:
: This study was conducted in accordance with the Declaration of Helsinki, Good Pharmacoepidemiology Practices, and local laws and regulations. All patients provided written informed consent before entering the study.
: Not applicable.
: HI received research funding from Sanofi K.K. and Sumitomo Dainippon Pharma Co. Ltd., and consultancy fees from JCR Pharmaceuticals Co., Ltd. and Takeda Pharmaceutical Company Limited. YW, RS, and YI are employees of Takeda Pharmaceutical Company Limited. JF is a former employee of Takeda Pharmaceutical Company Limited, and owns restricted stocks of Takeda Pharmaceutical Company Limited and GlaxoSmithKline K.K.
